Clinical translation of photoacoustic imaging using exogenous molecular contrast agents [Invited]
Biomedical Optics Express · 01.11.2025 · 16 (11) · 4353
DOI: 10.1364/boe.577244 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Biomedical Optics Express, online erschienen am 10.10.2025. Verfasst von Jingyi Miao und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Electrical and Computer Engineering, Rice University, 6100 Main St, Houston 77005, USA. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 240 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIBIB NIH HHS, National Institutes of Health, National Science Foundation.
Abstract (Originalsprache)
Photoacoustic imaging (PAI) combines optical contrast with acoustic detection to enable high-resolution, molecular imaging at clinically relevant depths. This review outlines the current status and future potential of contrast-enhanced PAI in human applications. We begin by discussing regulatory considerations surrounding both imaging devices and exogenous contrast agents, highlighting safety concerns, lack of standardized validation protocols, and barriers to the approval of novel agents. To accelerate clinical adoption, many studies have focused on repurposing FDA-approved agents such as indocyanine green, methylene blue, and clofazimine, which offer favorable optical properties and known safety profiles. We then review clinical applications of contrast-enhanced PAI across organ systems. In lymphatic imaging, PAI enables noninvasive visualization of lymphatic vessels and sentinel lymph nodes. Prostate imaging benefits from improved tumor delineation, and vascular applications leverage PAI to assess oxygen saturation and vascular remodeling. In gastrointestinal and hepatic imaging, PAI supports functional assessment and lesion detection with enhanced contrast. Emerging applications in neuro-oncology demonstrate the potential of PAI for intraoperative guidance and brain tumor imaging. Compared to fluorescence imaging, PAI provides deeper penetration and quantifiable contrast. Studies using both approved and investigational agents, including gold nanorods and targeted dye conjugates, highlight advances in imaging tumor margins. Progress in transcranial PAI and molecular probe design continues to broaden its capabilities. Together, these developments underscore the expanding clinical utility of contrast-enhanced PAI for real-time, functional, and molecular imaging.
Autor:innen und Institutionen
- Department of Electrical and Computer Engineering, Rice University, 6100 Main St, Houston 77005, USA.
- Department of Neurosurgery, University of Texas Medical Branch, 301 University Blvd, Galveston 77555, USA.
- Texas A&M University School of Engineering Medicine, 1020 Holcombe Blvd, Houston 77030, USA.
- Department of Convergence IT Engineering, Medical Device Innovation Center, Pohang University of Science and Technology (POSTECH), Pohang, 37673, Republic of Korea.
- Andrew and Peggy Cherng Department of Medical Engineering, California Institute of Technology, 1200 E California Blvd, Pasadena 91125, USA.
- ohdh@caltech.edu.
ORCID-Profile: Jingyi Miao, Lei S Li
Förderung
- NIBIB NIH HHS
- National Institutes of Health
- National Science Foundation
- Cancer Prevention and Research Institute of Texas
- Ministry of Education
- Ministry of Science and ICT, South Korea
Zitieren
APA
Miao, J., Luo, M., Kotwal, A., Hall, E., Oh, D., Valdes, P. A., & Li, L. S. (2025). Clinical translation of photoacoustic imaging using exogenous molecular contrast agents [Invited]. Biomedical Optics Express, 16(11), 4353. https://doi.org/10.1364/boe.577244
Vancouver
Miao J, Luo M, Kotwal A, Hall E, Oh D, Valdes PA, et al. Clinical translation of photoacoustic imaging using exogenous molecular contrast agents [Invited]. Biomedical Optics Express. 2025;16(11):4353. doi:10.1364/boe.577244
BibTeX
@article{Miao2025,
author = {Miao, Jingyi and Luo, Mingze and Kotwal, Alankar and Hall, Eric and Oh, Donghyeon and Valdes, Pablo A and Li, Lei S},
title = {Clinical translation of photoacoustic imaging using exogenous molecular contrast agents [Invited]},
journal = {Biomedical Optics Express},
year = {2025},
volume = {16},
number = {11},
pages = {4353},
doi = {10.1364/boe.577244}
}
EUVIMED